[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562836":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":49,"collaborators":51,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":28,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Autologous hematopoietic stem cell transplantation combined with CD19-CART","EXPERIMENTAL",null,[13],"Biological: Autologous hematopoietic stem cell transplantation combined with CD19-CART",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"BIOLOGICAL","Autologous CD19-CAR T cells were transfused +7 days after autologous hematopoietic stem cell transplantation",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"erlie EL Jiang","CONTACT","+86-15122538106","jiangerlie@ihcams.ac.cn",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,","RECRUITING","Tianjin","Tianjin Municipality","300000","China",{"type":34,"coordinates":35},"Point",[36,37],117.17667,39.14222,{"lat":37,"lon":36},[40,43,46],{"name":41,"role":22,"phone":23,"phoneExt":42,"email":24},"erlie EL Jiang, Doctor","022-23608602",{"name":44,"role":22,"phone":45,"phoneExt":42,"email":11},"rongli RL zhang","+86-13194633608",{"name":47,"role":48,"phone":11,"phoneExt":11,"email":11},"erlie EL jiang, Doctor","PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[52],{"name":53,"class":54},"Juventas Cell Therapy Ltd.","INDUSTRY","100562836",false,"NCT06608342","Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia","Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Adult patients with high-risk acute B-lymphoblastic leukemia\n* Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared\n* Eligible for autologous hematopoietic stem cell transplantation\n* No major organ dysfunction\n\nExclusion Criteria:\n\n* Combined with malignant tumors of other organs\n* With a serious infection that is not under control\n* Syphilis, AIDS, hepatitis B, hepatitis C, any one of them positive\n* Patients who have had an allergic reaction to the drugs used in this study or similar drugs\n* Other patients deemed unsuitable for inclusion by the investigators","ALL","18 Years","65 Years",{"count":65,"type":66},20,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.",[72],"Acute Lymphoblastic Leukemia ALL",[74,75],"inaticabtagene autoleucel","auto-HSCT","2024-09-19",{"date":78,"type":79},"2024-09-23","ACTUAL",{"date":81,"type":79},"2024-06-25",{"date":83,"type":66},"2028-05-30",{"name":5,"class":6},1]